Management of symptomatic locoregional recurrence during regional chemotherapy for colorectal liver metastases.
BACKGROUND
The incidence of symptomatic locoregional recurrence is doubled in patients receiving regional chemotherapy with hepatic arterial floxuridine infusion (HAI) compared with that in those with colorectal liver metastases treated by symptom control. This study assessed the management of symptomatic locoregional recurrence in HAI-treated patients with colorectal liver metastases.


METHODS
A retrospective review of all patients with colorectal liver metastases treated by HAI in one hospital over a 10-year period was carried out and the management of those who developed symptomatic locoregional recurrence was studied.


RESULTS
Twenty-three (14 per cent) of 166 HAI-treated patients with colorectal liver metastases developed symptoms of locoregional recurrence. Liver metastases were responding to HAI at the onset of symptoms in 19 (ten abdominal, nine pelvic recurrence) of the 23 patients. Resection of abdominal recurrence was possible in seven of the ten patients, with a median hospital stay of 14 days; there was one perioperative death. Resected patients survived a median of 15 months after resection of the recurrence, with five of seven remaining free of symptoms of locoregional recurrence. In contrast, six of nine HAI-responding patients with pelvic recurrence treated by external beam radiotherapy died from uncontrolled symptomatic pelvic disease.


CONCLUSIONS
Resection of abdominal recurrence achieved worthwhile palliation in patients with HAI-controlled liver metastases, but palliation of pelvic recurrence by irradiation was unsatisfactory.
Davies
M M
MM
Department of Gastrointestinal Surgery, Imperial College School of Medicine, Chelsea, UK.
Fordy
C
C
Burke
D
D
Allen-Mersh
T G
TG
D000008:Abdominal Neoplasms / Q000556:secondary*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D015179:Colorectal Neoplasms; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D010166:Palliative Care / Q000379:methods; D010386:Pelvic Neoplasms / Q000556:secondary*; D012189:Retrospective Studies
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine